Mode
Text Size
Log in / Sign up
N/A N=1,500 Randomized Single-blind Screening

Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes

Acute Coronary Syndrome · Depressive Symptoms

Enrolled (actual)
1,500
Serious AEs
0.0%
Results posted
Dec 2019
Primary outcome: Primary: Quality-Adjusted Life Years (QALYs) — -0.06; -0.06; -0.06 quality-adjusted life years (QALYs) — p=0.98

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Cognitive Behavioral Therapy (CBT) (Other); Antidepressant Medication (Drug); Standard Care (Other); Depressive symptom screener (Other); No intervention (Other)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Columbia University
Primary completion
Jul 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Quality-Adjusted Life Years (QALYs)
-0.06; -0.06; -0.06 0.98
SECONDARY
Depression-free Days
343.1; 351.3; 339.0
SECONDARY
Cost of Health Care Utilization
6745; 6204; 7440

Summary

The purpose of this study is to examine, in a randomized controlled trial, the benefits and costs of the American Heart Association's (AHA) advisory for depression screen and treatment of post-acute coronary syndrome patients.

Eligibility Criteria

Inclusion Criteria

  • With a documented acute coronary syndrome (ACS) within the past 2-12 months
  • Over the age of 21 years
  • Has access to a phone

Exclusion Criteria

Medical Exclusions:

  • Terminal illness (life expectancy <1 year as determined by physician/medical record) defined as, but not limited to:
  • NYHA class IV, ACC class D CHF requiring inotropes or mechanical assist devices or critical aortic stenosis without plan for correction
  • End-stage COPD/emphysema
  • Advanced cirrhosis with encephalopathy, varices, severe ascites
  • Severe rheumatologic diseases requiring frequent hospitalizations, and multiple cytotoxic agents and/or disease modifying drugs
  • Metastatic pancreatic, esophageal, colorectal or stomach cancer
  • Metastatic sarcoma, ovarian, melanoma or renal cell cancer
  • Metastatic breast cancer with multiple recurrences despite treatment
  • Advanced CNS malignancies
  • Recurrent hematologic malignancies with multiple recurrences despite treatment
  • Persistent AIDS, untreated or treated

Psychiatric Exclusions:

  • History of major depression
  • Currently receiving depression treatment
  • Dementia
  • History of bipolar disorder
  • History of psychosis
  • History of suicide attempt or self-inflicted injuries
  • Current alcohol or substance abuse

Other Exclusions:

  • Non-English and non-Spanish speaking
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01993017). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search